| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
|
J Clin Oncol
|
2006
|
2.91
|
|
2
|
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
|
J Clin Oncol
|
2004
|
2.50
|
|
3
|
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
|
Value Health
|
2009
|
1.61
|
|
4
|
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
|
J Clin Oncol
|
2012
|
1.58
|
|
5
|
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
|
Lung Cancer
|
2010
|
1.03
|
|
6
|
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
|
Cancer
|
2006
|
1.02
|
|
7
|
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.00
|
|
8
|
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
|
Int J Cancer
|
2002
|
0.90
|
|
9
|
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.
|
Lung Cancer
|
2005
|
0.88
|
|
10
|
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
|
Lung Cancer
|
2011
|
0.88
|
|
11
|
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.
|
Curr Opin Oncol
|
2005
|
0.85
|
|
12
|
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
|
Lung Cancer
|
2011
|
0.85
|
|
13
|
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.
|
Expert Opin Pharmacother
|
2007
|
0.83
|
|
14
|
Gefitinib for the treatment of non-small-cell lung cancer.
|
Expert Opin Pharmacother
|
2010
|
0.82
|
|
15
|
Survival improvement in thoracic cancer: progress from the last decade and beyond.
|
Lung Cancer
|
2007
|
0.82
|
|
16
|
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
|
Cancer
|
2003
|
0.81
|
|
17
|
Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
|
Oncology
|
2005
|
0.80
|
|
18
|
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).
|
Curr Med Res Opin
|
2010
|
0.79
|
|
19
|
Erlotinib in non-small cell lung cancer: a review.
|
Expert Opin Pharmacother
|
2005
|
0.78
|
|
20
|
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
|
Lung Cancer
|
2011
|
0.77
|
|
21
|
Awareness and understanding of cancer immunotherapy in Europe.
|
Hum Vaccin Immunother
|
2014
|
0.77
|
|
22
|
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
|
Lancet
|
2008
|
0.75
|
|
23
|
Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introduction.
|
Lung Cancer
|
2004
|
0.75
|
|
24
|
Perspectives on novel therapies for bronchial carcinoma.
|
Expert Opin Pharmacother
|
2005
|
0.75
|
|
25
|
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.
|
Curr Opin Oncol
|
2002
|
0.75
|
|
26
|
Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics.
|
Lung Cancer
|
2007
|
0.75
|